Manuscripts
Showing 1572 manuscripts.
Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study
Citation
Kristin Baltrusaitis, Jenny Huang, Barbara Heckman, Sarah Buisson, Dwight E. Yin, Ryan Milligan, Allison Agwu, Shawn Ward, Rohan Hazra, Carolyn Bolton-Moore, Conn Harrington, Aditya H. Gaur, Rodica M. Van Solingen-Ristea, IMPAACT 2017 Team, Cynthia C. McCoig, Adeola Adeyeye, Jared Kneebone, Vasiliki Chounta, Christiana Smith-Anderson, Elizabeth D. Lowenthal, Andres Camacho-Gonzalez, Jennifer Chapman, Ellen Chadwick, Rachel Ohrenschall, Allison Bearden, Katherine Calabrese, Herta Crauwels. Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study. Lancet HIV. 2024. 11: e222-e232. PMID: 38538161Year
          2024      
Journal
          Lancet HIV      
Study
          IMPAACT 2017      
Subsequent pregnancies in the IMPAACT 2010/VESTED Trial: high rate of adverse outcomes in women living with HIV
Citation
Roger Shapiro, Jeff Stringer, Grace Malonga, Renee Browning, Nahida Chakhtoura, Blandina Theophil Mmbaga, Tsungai P Mhembere, Ayotunde Omoz-Oarhe, Beatrice Nagaddya, Megeshinee Naidoo, Risa M Hoffman, Lee Fairlie, Shahin Lockman, Sean Brummel, IMPAACT 2010/VESTED Study Team, Lauren Ziemba, Anne Coletti, Lameck Chinula. Subsequent pregnancies in the IMPAACT 2010/VESTED Trial: high rate of adverse outcomes in women living with HIV. Journal of the International AIDS Society. 2024. 97: 150-155. PMID: 39742354Year
          2024      
Journal
          Journal of the International AIDS Society      
Study
          IMPAACT 2010      
Safety and pharmacokinetics of lopinavir/ritonavir oral solution in preterm and term infants starting before 3 months of age
Citation
Adrie Bekker, Jincheng Yang, Jiajia Wang, Mark F. Cotton, Mae Cababasay, Lubbe Wiesner, Jack Moye, Renee Browning, Firdose L. Nakwa, Helena Rabie, Avy Violari, Mark Mirochnick, Tim. R Cressey, Edmund V. Capparelli. Safety and pharmacokinetics of lopinavir/ritonavir oral solution in preterm and term infants starting before 3 months of age. Pediatric Infectious Disease Journal. 2024. 43: 355-360. PMID: 38190642Year
          2024      
Journal
          Pediatric Infectious Disease Journal      
Study
          P1106      
Safety and pharmacokinetics of oral and long-acting
injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre,
open-label, non-comparative, dose-finding st
  
  
    Citation
Aditya H. Gaur, Edmund V. Capparelli, Katherine Calabrese, Kristin Baltrusaitis, Mark A Marzinke, Cynthia McCoig, Rodica M. Van Solingen-Ristea, Sisinyana Ruth Mathiba, Adeola Adeyeye, John H. Moye, Barbara Heckman, Elizabeth D. Lowenthal, Shawn Ward, Ryan Milligan, Pearl Samson, Brookie M. Best, Conn M. Harrington, Susan L. Ford, Jenny Huang, Herta Crauwels, Kati Vandermeulen, Allison L. Agwu, Christiana Smith-Anderson, Andres Camacho-Gonzalez, Pradthana Ounchanum, Jared L. Kneebone, Ellen Townley, Carolyn Bolton Moore, IMPAACT 2017 Team. Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study. Lancet HIV. 2024. 11: e211-e221. PMID: 38538160Year
          2024      
Journal
          Lancet HIV      
Study
          IMPAACT 2017      
Cognitive Behavioral Therapy Factors Related to Outcomes in Depression Among Youth with HIV
Citation
Betsy D. Kennard, Larry K. Brown, Kristin Baltrusaitis, Miriam Chernoff, Graham J. Emslie, Jessica Jones, Sarah Buisson, Jaime Deville, Megan Wilkins, Amber Bunch, Chivon McMullen Jackson, Christy Beneri, David E. Shapiro, IMPAACT 2002 Team. Cognitive Behavioral Therapy Factors Related to Outcomes in Depression Among Youth with HIV. Cognitive Therapy and Research. 2024. 48: 781-790. PMID: 39664885Year
          2024      
Journal
          Cognitive Therapy and Research      
Study
          IMPAACT 2002      
Maternal immunity shapes biomarkers of germinal center development in HIV-exposed uninfected infants
Citation
John W. Sleasman, Guglielmo M. Venturi, Bernard M. Fischer, Julie J. Kim-Chang, Richard Barfield, Cliburn Chan, Kristina De Paris, Li Yin, Maureen M. Goodenow. Maternal immunity shapes biomarkers of germinal center development in HIV-exposed uninfected infants. Frontiers in Immunology. 2024. 15: 1443886. PMID: 39328414Year
          2024      
Journal
          Frontiers in Immunology      
Maternal-Child Human Immunodeficiency Virus Clinical Trials Networks across the Ages
Citation
Sharon Nachman. Maternal-Child Human Immunodeficiency Virus Clinical Trials Networks across the Ages. Clinics in Perinatology. 2024. 51: 935-949. PMID: 39487030Year
          2024      
Journal
          Clinics in Perinatology      
Infants Receiving Very Early ART Have High CD4 Counts in the First Year of Life
Citation
Deborah Persaud, Ellen G. Chadwick, Jennifer Jao, IMPAACT P1115 Team, Mark F. Cotton, Yvonne Bryson, Anne Coletti, Theodore D. Ruel, Stephen A. Spector, Christina Reding, Kira Bacon, Diane Costello, Charlotte Perlowski, Maria Leticia Santos Cruz, Josphat Kosgei, Sai Majji, Bryan S. Nelson, Dwight E. Yin, Camlin Tierney, Patrick Jean-Philippe. Infants Receiving Very Early ART Have High CD4 Counts in the First Year of Life. Clinical Infectious Diseases. 2023. 76: e744-e747. PMID: 36031390Year
          2023      
Journal
          Clinical Infectious Diseases      
Study
          P1115      
Pharmacokinetics, tolerability, and safety of doravirine and doravirine/lamivudine/tenofovir disoproxil fumarate fixed dose combination tablets in adolescents living with HIV: Week 24 results from IMPAACT 2014
Citation
Hong Wan, Hedy Teppler, Kathryn P Gray, Ellen Townley, Mounika Yedla, Jack Moye, Brookie M. Best, Nicole H. Tobin, IMPAACT 2014 Study Team, Havilland Campbell, Katie McCarthy, Rachel Scheckter, Linda Aurpibul, Pradthana Ounchanum, Supattra Rungmaitree, Hassena Cassim, Elizabeth McFarland, Patricia Flynn, Ann J Melvin, Ellen Cooper, Ka Lai Yee, Chelsea Krotje. Pharmacokinetics, tolerability, and safety of doravirine and doravirine/lamivudine/tenofovir disoproxil fumarate fixed dose combination tablets in adolescents living with HIV: Week 24 results from IMPAACT 2014. Journal of AIDS. 2023. PMID: 36215957Year
          2023      
Journal
          Journal of AIDS      
Study
          IMPAACT 2014      
Self-reported Antiretroviral Adherence: Association With Maternal Viral Load Suppression in Postpartum Women Living With HIV-1 From Promoting Maternal and Infant Survival Everywhere, a Randomized Controlled Trial in Sub-Saharan Africa and India
Citation
David E. Shapiro, Patience Atuhaire, Taha E Taha, Bonus Makanani, Lameck Chinula, Maxensia Owor, Dhayendre Moodley, Tsungai Chipato, Katie McCarthy, Patricia M. Flynn, Judith Currier, Mary Glenn Fowler, Amita Gupta, Nishi Suryavanshi, Neetal Nevrekar, Kevin Butler. Self-reported Antiretroviral Adherence: Association With Maternal Viral Load Suppression in Postpartum Women Living With HIV-1 From Promoting Maternal and Infant Survival Everywhere, a Randomized Controlled Trial in Sub-Saharan Africa and India. Journal of the International AIDS Society. 2023. 92: 76-83. PMID: 36170749Year
          2023      
Journal
          Journal of the International AIDS Society      
Study
          1077FF,          1077BF